Business Numinus completes Novamind acquisition, upgrades leadership team Novamind's clinics in Utah and Arizona will continue to operate as their current brand until later this year Natalia Buendia CalvilloJune 14, 2022
Culture Numinus announces Music as Medicine event series Series of concerts across the U.S. and Canada will explore music’s role in psychedelic-assisted therapy Ryan GarnerMay 3, 2022
Business Recent acquisitions help Numinus bolster revenue 240 per cent year-over-year Numinus' gross margin improved to 29.1 per cent during Q2 2022 following acquisitions of Mindspace Psychology Services Inc. and the Neurology Centre of Toronto Ryan GarnerApril 19, 2022
Business Numinus to enter US psychedelics market via $26.2M Novamind acquisition The transaction is expected to close around June Natalia Buendia CalvilloApril 12, 2022
Business Numinus approved to study ayahuasca and San Pedro in Canada Used in sacred traditions for centuries, the firm says research will bring their medicinal benefits to a larger audience Natalia Buendia CalvilloMarch 9, 2022
Business Numinus uplists to OTCQX Best Market Stock will start trading at market open Thursday under the symbol NUMIF Natalia Buendia CalvilloJanuary 26, 2022
Business Numinus ends fiscal year with revenue up 72% to $1.5M, losses of $19M The psychedelics firm has been aggressively expanding lab space while pushing ahead with clinical trials Natalia Buendia CalvilloDecember 10, 2021
Canada Numinus set to open Canada’s first psychedelics neurology centre The Vancouver based firm is acquiring the Neurology Centre of Toronto in a cash and stock deal Natalia Buendia CalvilloJuly 7, 2021